Slide 1: FY 2021 Results
FY 2021 RESULTS March 16, 2022
Slide 2: Disclaimer
Disclaimer In General. This disclaimer applies to this presentation and any oral comments of any person presenting it. This document, taken together with any such oral comments, is referred to herein as the “Presentation”. This Presentation has been prepared by DiaSorin S.p.A. (“DiaSorin” or the “Co
Slide 3: Forward-looking statements
Forward-looking statements This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which DiaSorin operates and the beliefs and assumptions of the management of DiaSorin. In addition, the management of DiaS
Slide 4: Financial Highlights
Financial Highlights* Change Data in €/mln FY’21 @ current @ CER Revenues 1,237.7 +40.4% +41.2% CLIA ex Vitamin D +24.0% +24.5% Vitamin D (CLIA) +7.8% +9.4% ELISA tests -14.0% -13.0% Molecular tests +27.4% +29.3% Instruments & Others -3.1% -2.5% Luminex 195.0 n.m. n.m. Adjusted EBITDA 543.1 +41.0% +
Slide 5: FY 2021 key facts
FY 2021 key facts Business Development Convertible bond loan to complete the acquisition of Luminex • Luminex acquisition: the closing of the transaction is effective starting from July 14, 2021. Through • Placement of an unsecured equity-linked senior bond loan for € 500 million with maturity to 20
Slide 6: Managerial outlook on FY 2021 revenues
Managerial outlook on FY 2021 revenues Total FY Group revenues (data in €/mln) Evolution of the business in the quarter Data @CER Data @CUR Positive results, driven by three separate trends: • BUSINESS EX-COVID (at constant perimeter§): on a strong recovery path, +41% +40% +14.8% @CER vs. FY'20, wit
Slide 7: FY 2021 revenue growth by geography and technology
FY 2021 revenue growth by geography and technology FY’21 vs. FY’21 vs. BY GEOGRAPHY§ BY TECHNOLOGY§ FY’20 FY’20 EUROPE & AFRICA • Positive top line trend, thanks to the contribution of COVID-19 testing +25.9% reported +24.0% CLIA EX VITAMIN D TESTS and the recovery of ex-COVID sales. @ CER +24.5% US
Slide 8: FY 2021 revenues: managerial view
FY 2021 revenues: managerial view BY GEOGRAPHY BY TECHNOLOGY Licensed Technologies 7.8% FY’21 FY'21 North America Direct 43.9% Immunodiagnostics Molecular Diagnostics 56.7% 35.5% Europe Direct 39.1% Rest of the World 17.0% Luminex Revenues' trend • EXCELLENT PERFORMANCE, of both the MOLECULAR BUSINE
Slide 9: FY'21 profitability profile
FY'21 profitability profile (data in €/mln) 43.9% 43.7% 1,238 881 • Luminex acquisition had an expected dilutive effect on the Group profitability profile in H2, that will progressively decline over the next 543 quarters as a consequence of the integration process and its related synergies 385 2020
Slide 10: FY 2022 Company Guidance
FY 2022 Company Guidance FY 2022 GUIDANCE at 2021 CER: ▪ REVENUES: ex-COVID revenues growing at +24.0%, COVID-19 related products revenues at € 150 million, resulting in total revenues broadly in line with 2021 (approx. -2% vs. FY'21) ▪ ADJUSTED EBITDA* MARGIN: approx. 35% * With reference to the Ad
Slide 11: Financial schemes
Financial schemes 11
Slide 12: Income Statement
Income Statement FY Change (Amounts in million of euros) 2020 2021 amount % Net Revenues 881.3 1,237.7 +356.4 +40.4% Cost of sales (278.4) (412.9) -134.5 +48.3% Gross profit 602.9 824.8 +221.9 +36.8% 68.4% 66.6% -177 bps Sales and marketing expenses (144.1) (211.3) -67.3 +46.7% Research and developm
Slide 13: Adjusted Income Statement
Adjusted Income Statement* FY Change (Amounts in million of euros) 2020 2021 amount % Net Revenues 881.3 1,237.7 +356.3 +40.4% Cost of sales (278.4) (406.7) -128.3 +46.1% Gross profit 602.9 831.0 +228.1 +37.8% 68.4% 67.1% -127 bps Sales and marketing expenses (144.1) (197.1) -53.0 +36.8% Research an
Slide 14: Reconciliation to consolidated financial statements
Reconciliation to consolidated financial statements Data in €/mln Gross Margin EBITDA2 EBIT Fiscal Impact Net Profit 824.8 515.5 419.5 n.a. 310.7 IFRS Financial Statements Measures % on Revenues 66.6% 41.7% 33.9% 25.1% Adjustments 6.2 6.2 6.2 (1.5) 4.7 Fair value measurement of the initial Luminex i
Slide 15: Balance Sheet
Balance Sheet (Amounts in million of euros) 12/31/2020 12/31/2021 Change Goodwill and intangibles assets 356.7 1,943.4 +1,586.6 Property, plant and equipment 140.5 276.2 +135.7 Other non-current assets 35.3 42.6 +7.3 Net working capital 217.9 361.9 +144.0 Other non-current liabilities (99.5) (270.2)
Slide 16: Cash flow statement
Cash flow statement FY (Amounts in million of euros) 2020 2021 Cash and cash equivalents at the beginning of the period 157.6 339.9 Cash provided by operating activities 304.6 400.7 Cash used in investing activities (73.0) (110.4) Cash provided/(used) in financing activities (90.0) 1,273.7 Acquisiti
Slide 17: DiaSorin
DiaSorin